Wegovy Resolution Dates: When Pen Strengths Return

Introduction

The FDA declared the Wegovy® shortage resolved on February 21, 2025, but pharmacy-level supply for specific strengths still varies in 2026. The phrase “resolution date” means different things at different levels of the supply chain. This piece walks through what Novo Nordisk’s guidance projects for each strength and what to expect.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Does “Resolution Date” Actually Mean?

Three different things. At the FDA level, a resolution date is when the agency removes a drug from the Drug Shortage Database, indicating the manufacturer has caught up to demand. Wegovy was removed February 21, 2025.

Quick Answer: FDA removed Wegovy from the shortage list on February 21, 2025

At the manufacturer level, a resolution date is when a specific strength returns to normal distribution into the wholesale channel. Novo Nordisk publishes guidance on this through investor calls and press releases.

At the pharmacy level, a resolution date is when individual retail and mail-order pharmacies can reliably keep that strength in stock. This is what patients actually experience and it typically lags manufacturer resolution by 4 to 8 weeks.

When you read “Wegovy resolution date Q3 2026,” you need to ask which definition. Manufacturer Q3 2026 might mean retail Q4 2026.

Wegovy 0.25 Mg Resolution Status

Resolved at all levels through 2025 and 2026. The 0.25 mg starter pen has been consistently stocked since early 2025. Novo Nordisk explicitly prioritized this strength to keep new patient titration flowing during the supply ramp.

If your pharmacy can’t fill 0.25 mg in 2026, the issue is local rather than systemic. Try a different pharmacy in your area. The Wegovy Stock Locator at wegovy.com shows pharmacy-level inventory.

Wegovy 0.5 Mg Resolution Status

Resolved at all levels. The 0.5 mg titration dose has been consistently stocked since mid-2025. Patients moving from 0.25 mg to 0.5 mg during weeks 5-8 of therapy generally don’t experience supply gaps.

Wegovy 1.0 Mg Resolution Status

Largely resolved at the manufacturer level through 2025. Retail pharmacy supply normalized in Q4 2025 to Q1 2026. Occasional 3 to 7 day gaps occur but are not systemic.

If you can’t find 1.0 mg locally, mail-order through your insurance plan typically has it. NovoCare direct ships it consistently.

Wegovy 1.7 Mg Resolution Status

Manufacturer-level resolution is targeted for Q2 to Q3 2026 per Novo Nordisk’s Q4 2025 investor guidance. Pharmacy-level normalization is expected Q3 to Q4 2026.

The 1.7 mg strength is the second-most-delayed Wegovy dose at retail in 2026. It’s both a titration step and a long-term maintenance dose for patients who don’t tolerate or don’t need 2.4 mg. The combined demand profile makes it harder to stock consistently.

Specific guidance: Novo Nordisk reported in its Q1 2026 earnings call that 1.7 mg distribution had improved compared to 2025 but still showed periodic regional gaps lasting 1 to 2 weeks. Full normalization expected by year-end 2026.

Wegovy 2.4 Mg Resolution Status

This is the slowest strength to fully normalize. Manufacturer-level resolution is targeted for Q4 2026 per Novo’s most recent guidance. Pharmacy-level normalization is expected Q1 to Q2 2027.

The 2.4 mg dose is the maintenance dose where the largest patient cohort sits. It’s also the dose used in STEP 1 (Wilding et al. 2021 NEJM) where 14.9% mean weight loss at 68 weeks was reported, and in SELECT (Lincoff et al. 2023 NEJM) where the 20% MACE reduction was demonstrated. Cardiovascular indication-driven prescribing adds steady demand pressure.

Novo Nordisk has stated publicly that 2.4 mg fill-finish capacity is the company’s top operational priority for 2026. Multiple new fill-finish lines came online in late 2025, but ramp-up to full validated commercial output takes quarters.

Specific channels in 2026: NovoCare direct typically ships 2.4 mg within 7 to 12 business days. Mail-order through insurance plans typically fills 2.4 mg within 5 to 10 business days. Retail pharmacy availability varies by region, with median restock times around 11 days at chain pharmacies and 8 days at independents per early 2026 surveys.

Key Takeaway: Starter strengths (0.25 mg, 0.5 mg) have been stable through 2025 and 2026

Why Does 2.4 Mg Take Longer Than 1.7 Mg?

Three reasons. Volume: 2.4 mg is the largest single-SKU pen volume in the Novo Nordisk portfolio. Demand growth: SELECT and FLOW indication approvals expanded the eligible patient base for the maintenance dose more than for titration doses. Manufacturing concentration: the 2.4 mg pen is filled at a specific set of fill-finish lines that have been the company’s expansion focus.

The pen is dose-specific, not just a different label on a generic pen. Each strength requires its own fill volume and dosing calibration in the autoinjector. You can’t easily swap production capacity between strengths.

What Does Novo Nordisk’s Manufacturing Expansion Look Like?

The company invested more than $6 billion in semaglutide manufacturing expansion through 2025, including the Catalent acquisition completed in late 2024 for $16.5 billion (covering three large fill-finish sites). Additional fill-finish lines were brought online at the company’s existing Kalundborg, Denmark facility and at Bagsvaerd, Denmark.

New U.S. fill-finish capacity in North Carolina came online in late 2025 and reached full validated production in early 2026.

Novo Nordisk’s investor guidance projects total semaglutide manufacturing capacity growing roughly 50% from 2025 to 2027, with most growth concentrated in fill-finish for higher-dose pens.

What About Future Capacity?

The company has guided to continued expansion through 2027 and 2028 to support both the existing obesity and cardiovascular indications and any future indication approvals. The FLOW chronic kidney disease indication (approved 2026 expected) and additional cardiovascular subgroup approvals could expand demand further.

Pricing pressure from Medicare negotiation (semaglutide is in the second round of Medicare negotiated drugs, with new prices effective January 2027) may shift the demand picture. Lower Medicare prices typically mean higher volume, not lower.

How Does This Compare to Ozempic®?

Ozempic shares fill-finish capacity with Wegovy at certain Novo facilities. Resolution dates for Ozempic strengths have been mostly Q3 to Q4 2025, ahead of Wegovy because diabetes indication prescribing is less elastic than obesity prescribing.

The 2 mg Ozempic pen, which is the most concentrated dose, sees the longest delays among Ozempic strengths, similar to how 2.4 mg Wegovy is the slowest among Wegovy strengths.

How Do These Resolution Dates Affect My Planning?

Three implications. If you’re on 0.25 mg or 0.5 mg, supply is not an issue in 2026. Plan normally.

If you’re on 1.0 mg or 1.7 mg, expect occasional regional gaps lasting 1 to 2 weeks. Build a 14-day buffer into your refill cycle. Consider 90-day mail-order.

If you’re on 2.4 mg, build a 21-day buffer. Use mail-order or NovoCare direct if available. Have a contingency plan with your prescriber for a temporary downstep if a longer gap hits.

By Q3 to Q4 2027, all Wegovy strengths should be at consistent retail availability everywhere absent new demand surges from indication approvals.

Bottom line: NovoCare direct and mail-order channels reach restock dates faster than retail pharmacies

FAQ

Is Novo Nordisk Going to Miss Its Resolution Targets?

Possibly. Manufacturer guidance assumes no major demand surges. New indication approvals or pricing changes could shift the picture.

Where Does Novo Publish Official Resolution Dates?

The FDA Drug Shortage Database for federal status, Novo Nordisk’s investor relations pages for capacity guidance, and the Wegovy Stock Locator at wegovy.com for pharmacy-level data.

Why Doesn’t the FDA Relist Wegovy If 2.4 Mg Is Still Tight?

The FDA shortage list is a binary federal designation based on national supply and demand. Localized or strength-specific gaps don’t trigger relisting if total national supply meets total national demand on average.

Is Compounded Semaglutide Still Available While 2.4 Mg Is Tight?

Yes, through state-licensed 503A pharmacies on a patient-specific basis when there’s documented clinical justification. The free TrimRx assessment quiz reviews whether your situation qualifies.

Should I Switch to Zepbound® While Waiting for Wegovy 2.4 Mg?

That’s a clinical decision involving your prescriber. SURMOUNT-5 showed tirzepatide produces larger mean weight loss than semaglutide head-to-head, but switching requires new PA and re-titration.

Will Prices Go up as Supply Normalizes?

Novo Nordisk has held wholesale acquisition costs steady through 2025 and 2026. Medicare negotiation takes effect 2027 and may lower prices for that population.

Where Can I See Real-time Pharmacy Stock?

The Wegovy Stock Locator at wegovy.com. The tool refreshes every few hours from wholesale and pharmacy data. Always call to confirm before driving.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.